⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivopril SCHEMBL678364 | 1.00 | — | — | |
| Pivopril SCHEMBL120071 | 1.00 | — | — | |
| SCHEMBL682441 | 0.99 | — | — | |
| SCHEMBL683304 | 0.99 | — | — | |
| SCHEMBL683661 | 0.99 | — | — | |
| SCHEMBL683238 | 0.95 | — | — | |
| SCHEMBL683559 | 0.86 | — | — | |
| SCHEMBL683645 | 0.86 | — | — | |
| SCHEMBL10739009 | 0.85 | — | — | |
| SCHEMBL683648 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119325377-A | Method for treating focal segmental glomerulosclerosis with atrasentan | 奇努克治疗公司 | 2025-01-17 | — | — | CN | claimed |
| US-12121509-B2 | Methods of improving renal function | CHINOOK THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| WO-2023225163-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230364055-A1 | METHODS OF IMPROVING RENAL FUNCTION | CHINOOK THERAPEUTICS, INC. | 2023-11-16 | — | — | US | claimed |
| US-20230270718-A1 | METHODS OF TREATING DIABETIC KIDNEY DISEASE | CHINOOK THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | claimed |
| WO-2023047203-A1 | COMBINATION OF OMZOTIROME AND ANTIDIABETIC AGENT, ANTIHYPERTENSIVE AGENT OR ANTI-DYSLIPIDEMIC AGENT | TORRENT PHARMACEUTICALS LTD (IN) | 2023-03-30 | — | — | WO | claimed |
| EP-0527720-A1 | THERAPEUTIC AGENTS. | BOOTS CO PLC (GB) | 1993-02-24 | — | — | EP | claimed |
| EP-0336950-B1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1992-01-22 | — | — | EP | claimed |
| WO-1990010445-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1990-09-20 | — | — | WO | claimed |
| EP-0272177-B1 | PHARMACEUTICAL COMPOSITION CONTAINING DILTIAZEM AND AN INHIBITOR OF THE ENZYME-TRANSFORMING ANGIOTENSIN | SYNTHELABO (FR) | 1990-07-04 | — | — | EP | claimed |
| EP-0351017-A2 | Pharmaceutical composition useful for the treatment of cardiovascular diseases | ZAMBON GROUP S.p.A. (IT) | 1990-01-17 | — | — | EP | claimed |
| EP-0336950-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | claimed |
| WO-1989003691-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-05-05 | — | — | WO | claimed |
| EP-0272177-A1 | Pharmaceutical composition containing diltiazem and an inhibitor of the enzyme-transforming angiotensin | SYNTHELABO (FR) | 1988-06-22 | — | — | EP | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |